文献速递甲状腺疾病

达拉非尼与曲美替尼用于放射性碘难治性突变型晚期分化型甲状腺癌再分化及治疗的药代动力学/药效学研究

Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2023-10-12

该回顾性单中心研究纳入15例接受再分化策略的放射性碘难治性突变型晚期分化型甲状腺癌患者,评估达拉非尼、其活性代谢物羟基达拉非尼及曲美替尼的血浆暴露与剂量限制性毒性及放射性碘再摄取的关系。结果显示曲美替尼相关剂量限制性毒性与较高的曲美替尼AUC相关,而放射性碘再摄取与较低的达拉非尼AUC及较高的羟基达拉非尼/达拉非尼AUC比值相关。作者认为血浆药物监测可能有助于指导再分化治疗的临床实践。

要点

  • 曲美替尼相关剂量限制性毒性患者末次曲美替尼AUC显著高于无毒性患者(390 vs 215 ng/mL·h-1,p=0.008)。
  • 达拉非尼相关剂量限制性毒性患者达拉非尼AUC较高(9265 vs 6953 ng/mL·h-1,p=0.09)。
  • 实现放射性碘再摄取患者达拉非尼AUC较低(6990 vs 9764 ng/mL·h-1,p=0.014),羟基达拉非尼/达拉非尼AUC比值较高(1.11 vs 0.71,p=0.0047)。

核心结论

  • 数据提示剂量限制性毒性发生与曲美替尼血浆暴露相关,放射性碘再摄取的实现与达拉非尼血浆暴露(AUC及羟基达拉非尼/达拉非尼AUC比值)相关。
  • 这些数据提示血浆药物监测可能有助于指导再分化治疗的临床实践。

研究设计与样本

  • 回顾性单中心研究,回顾性审查2014年3月至2021年12月期间在本机构接受肿瘤再分化策略并进行了达拉非尼、其活性代谢物羟基达拉非尼及曲美替尼血浆浓度测定的患者电子病历。
  • 22例接受再分化策略治疗的患者中,15例纳入本研究。
  • 估计了达拉非尼(AUCDAB)、羟基达拉非尼(AUCOHD)和曲美替尼(AUCTRA)的谷浓度(Cminpred)和总血浆药物暴露(曲线下面积,AUC)。

主要发现

  • 8例(62%)患者发生达拉非尼相关剂量限制性毒性,9例(64%)患者发生曲美替尼相关剂量限制性毒性。
  • 发生曲美替尼相关剂量限制性毒性的患者末次AUCTRA显著高于无剂量限制性毒性患者的平均AUCTRA(390,IQR:67 vs 215,IQR:91 ng/mL·h-1;p=0.008)。
  • 发生达拉非尼相关剂量限制性毒性的患者AUCDAB高于其他患者(9265 ng/mL·h-1 vs 6953 ng/mL·h-1;p=0.09)。
  • 未发现与剂量限制性毒性发生相关的临床和人口学特征。
  • 15例患者中9例(60%)实现肿瘤再分化。

关键数值与推荐

  • 曲美替尼相关剂量限制性毒性患者末次AUCTRA为390(IQR:67)ng/mL·h-1,无剂量限制性毒性患者平均AUCTRA为215(IQR:91)ng/mL·h-1,p=0.008。
  • 达拉非尼相关剂量限制性毒性患者AUCDAB为9265 ng/mL·h-1,其他患者为6953 ng/mL·h-1,p=0.09。
  • 实现放射性碘再摄取患者AUCDAB为6990 ng/mL·h-1,未实现者为9764 ng/mL·h-1,p=0.014。
  • 实现放射性碘再摄取患者AUCOHD/DAB比值为1.11,未实现者为0.71,p=0.0047。
  • 15例患者中9例(60%)实现肿瘤再分化。

临床怎么用

  • 作者认为血浆药物监测可能有助于指导再分化治疗的临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored the exposure-toxicity relationship for dose-limiting toxicity (DLT) onset in patients treated with dabrafenib and/or trametinib and investigated whether plasma exposure was associated with RAI reuptake. Methods: We conducted a retrospective monocentric study in which we reviewed the electronic medical records of patients treated in our institution with a tumor redifferentiation strategy, for whom plasma concentration of dabrafenib, its active metabolite hydroxy-dabrafenib, and trametinib was measured. Trough concentrations (Cminpred) and total plasma drug exposure (area under the curve, AUC) of dabrafenib (AUCDAB), hydroxy-dabrafenib (AUCOHD), and trametinib (AUCTRA) were estimated. Results: Of the 22 patients treated in a redifferentiation strategy between March 2014 and December 2021, 15 were included in this study. A dabrafenib- or trametinib-related DLT was experienced by 8 (62%) and 9 (64%) patients, respectively. Patients who experienced a trametinib-related DLT exhibited a significantly higher last AUCTRA than the average AUCTRA of patients who had no DLT (390, IQR: 67 vs. 215, IQR: 91 ng/mL·h-1, respectively; p = 0.008). Patients who experienced a dabrafenib-related DLT had a higher AUCDAB than observed in other patients (9265 ng/mL·h-1 vs. 6953 ng/mL·h-1, respectively; p = 0.09). No clinical and demographical characteristic was associated with the DLT onset. Overall, 9 of 15 (60%) patients demonstrated tumor redifferentiation. Patients in whom RAI reuptake was achieved had significant lower AUCDAB (6990 ng/mL·h-1 vs. 9764 ng/mL·h-1, p = 0.014; respectively) compared with patients who did not. Moreover, the relative exposure ratio of AUCOHD/DAB was significantly higher in patients who achieved RAI reuptake (1.11 vs. 0.71, respectively; p = 0.0047). Conclusions: Our data suggest a relationship between DLT onset and trametinib plasma exposure, as well as an association between achievement of RAI reuptake and dabrafenib plasma exposure (AUC and ratio of AUCOHD/DAB). These data imply that the use of plasma drug monitoring could be helpful in guiding clinical practice in redifferentiation treatment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Balakirouchenane D, Seban R, Groussin L, et al. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer. Thyroid. 2023. PMID: 37725566. doi:10.1089/thy.2023.0228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。